S
toma care is big business: in 2012, £228m (€269m; $363m) worth of ostomy bags and accessories were dispensed in England alone.
1 But this market performs poorly and fails patients and the NHS. The NHS buys excessive quantities of appliances, and patients routinely receive equipment that isn't needed.
Stoma care is the support of patients after stoma surgery, typically for a colostomy, ileostomy, or urostomy, in which the bowel or bladder is diverted outside the abdomenthis is known as a stoma. More than 102 000 people in the UK have a stoma and will wear a stoma bag either temporarily or for the rest of their life.
2 People with stomas are cared for by specialist stoma care nurses, who make sure they can look after their stoma when they go home and advise them which products to use.
However, a recent BBC Radio 4 You and Yours investigation found that 75% of stoma nurses in England, Wales, and Northern Ireland are sponsored by the companies that manufacture ostomy supplies, with NHS hospitals receiving money to discharge people with stomas as customers of that company.
3 There are no generics in this market.
After discharge, ostomy supplies are delivered by the sponsor company's own dispensing appliance contractor, which requests prescriptions directly from the general practitioner. As most general practitioners have limited knowledge of stoma care they rely on the company and the patient to write the prescription. This effectively means that the clinical professional expert, the stoma care nurse, is absent from the decision making process.
Even though people with stomas in the UK have free access to a great range of advanced ostomy products, they are often unaware of the choices available to them. They find it difficult to navigate the smoke and mirrors of the market.
Stoma care nurses do a great job, and their patients value them highly. However, when company sponsorship affects their advice and care it's not surprising that patients aren't always aware of the full range of products available to them. Scotland ended sponsorship of stoma care nurses in 2006.
Conservative MP Jonathan Evans last year raised the issue in parliament: "It's clear that if you have someone that is a health professional and they advise you about your care and that person is paid for by the manufacturer of a product, big issues around conflicts of interest arise." 3 4 In response, competing companies producing stoma care products have had to evolve into slick sales and marketing machines using advertising and promotional tactics to switch patients to their products.
Many people with a stoma are well informed and empowered. Some are members of local support groups, attend events, are active users of internet forums, and attend clinics run by stoma care nurses. But most have little information and irregular nurse appointments, and turn to companies rather than the medical profession for advice.
It was this lack of impartiality and my experiences as a patient that motivated me to set up a new social enterprise, Patient Choice. It has no financial incentive to push particular, or additional, products. Profits are donated to healthcare charities.
Patients should never have to pay for ostomy supplies, but the current system encourages patients to use more rather than to use what's best for them. The problems with the stoma care market are due to basic economics: financial incentives are geared towards delivering more, regardless of clinical need, and the core marketing message for many products is that they are free-so why not have them?
I have firsthand experience of the waste this causes. Ostomy Lifestyle is a national stoma support charity I founded in 2007 to help people affected by stoma surgery. It's international aid project, OstomyAid, takes surplus stoma products from the UK and distributes them abroad. I saw brand new, unwanted ostomy appliances delivered almost daily, often by people who said they didn't know why they were sent so much.
Ultimately, what matters is improving patient care. No individual company or nurse should shoulder the blame; it is the system that's broken. Nurses aren't supported to do their job as clinicians, and private businesses are allowed to exploit patients for financial reward. Not only is the stoma care market failing the taxpayer and the NHS but it is encouraging companies to oversupply products of questionable value to the patient.
We need a market that is transparent and offers independent, impartial advice, regardless of profit. A social venture such as Patient Choice is the start of this process. Once patients see that they can receive a good, independent service, which makes profits to help other patients rather than for shareholders, more people will join us. And when that happens the market might start to change. 11 So what is the motivation to misuse these drugs? Users describe the effects as the "ideal psychotropic drug," "great euphoria," "disassociation," and "opiate buzz," and are achieving these effects by taking large quantities as a single dose.
10 Accordingly there is a growing black market, and these drugs are being bought through online pharmacies.
The US recognises the problems associated with pregabalin, which has now become a scheduled drug under the Controlled Substance Act.
12 Is the UK ignoring the misuse of pregabalin and gabapentin? Should we re-examine the so called evidence for gabapentin and pregabalin and consider alternatives? 13 14 For the risk from iatrogenic harm is bad medicine indeed. Time to tackle the rise and rise of gabapentin and pregabalin prescribing?
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People have died from the drugs I have prescribed. I rationalised that these drugs were prescribed in good faith, in line with guidelines, and deaths were the result of misuse. But this offers no comfort to my sense of guilt.
Prescription drug misuse is a problem, especially psychoactive drugs such as opioids and benzodiazepines. And there is an iatrogenic epidemic of harm in the US, with nearly 15 000 deaths annually from prescribed painkillers. This is the tiny tip of an abuse iceberg, with an estimated 12 million Americans misusing these drugs recreationally. 1 We have a social and professional responsibility to be cautious in how we prescribe psychoactive drugs. Increasingly, I confront drug seeking behaviours for different drugs-gabapentin and pregabalin. Could it be that these seemingly harmless epilepsy drugs are being misused?
Gabapentin and pregabalin are in fact also licensed for neuropathic pain, and pregabalin for general anxiety disorder. These are common and chronic conditions, together affecting 20% to 40% of the population.
2 3 Their prescribing is anointed by Cochrane reviews 4 5 and a NICE guideline 6 : gold plated evidence of benefit. Gabapentin and pregabalin are being prescribed freely and rapid dose up titration is recommended. Pregabalin prescribing has increased by 350% in just five years, to 2.7 million scripts. Likewise gabapentin prescribing has increased 150% in five years, with 3.5 million scripts.
7 This stellar prescribing growth seems set to continue. And this is big business too, with combined sales worth £200m a year.
7 But a word of caution: pain and anxiety symptoms are subjective, with wide variation in reported prevalence.
2 The longest neuropathic pain study lasted a mere 13 weeks, 6 and highly psychoactive drugs are difficult to compare with placebo.
And there is increasing published evidence of concern about the abuse of pregabalin and gabapentin, [8] [9] [10] and these drugs are now commonly being We stand on the shoulders of giants, but it can be an uncomfortable perch. "This will help your cough," I said firmly, summoning up all the authority of our ancient profession, of our eternal battle against superstition and ignorance, of titans like Harvey and Lister and Semmelweiss and Pasteur, and of the sacrifices they made often in the face of persecution and ridicule.
"Simple linctus 10 mL qid," I wrote, and the ghosts of the titans shrank back in disgust. Lister made a retching noise, and Semmelweiss gave me the fingers.
But what can I do, I asked. There is a long cultural tradition of prescribing bottles. The placebo effect may be significant; it's a gesture of concern, that I'm taking the problem seriouslyand it's safe: "first do no harm" and all.
The ghost of Galileo appeared, waving his bloody thumbs at me. "Look at these bad boys," he said anchor, and getting sick of all this, like, science. Climate change denial, creationism: at last I understood the attraction, the simplicity of it all. Science is just too conflicting and confusing; fantasy is safer.
"Confusion is not an ignoble state, lad," said kindly old Bones McCoy. "Sometimes there's no right thing to do, just the least wrong thing; that's real medicine for you." "Remember," said Van Helsing, "a firm stab, through the heart." "Surely you can't be serious," I protested.
" "Some bastards even tried to poison me," chipped in Galen. "And for you to prescribe sugar flavoured water is spurious and deceitful. A Cochrane review of the use of antitussives in patients with acute cough showed no clear benefit for duration of cough." 1 "That's pretty rich," I said, "coming from someone whose anatomical knowledge was gained from dissecting monkeys." "That's true, monkey boy," said Vesalius. "You proposed that the interventricular septum was permeable; set the science of anatomy back a thousand years." "Hey," said Galen, "they wouldn't let me use gladiators; I tried it once and then there was all this 'I am Spartacus!' shit."
By now I was feeling like a Fox News
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